Sanofi, GSK start phase II COVID-19 vaccine study

By The Science Advisory Board staff writers

February 22, 2021 -- Sanofi and GlaxoSmithKline (GSK) are starting a large phase II study of their COVID-19 vaccine.

The two pharmas are developing an adjuvanted recombinant protein vaccine. Their phase II study, which will enroll 720 adult volunteers, will evaluate three different antigen doses to determine the best strategy for phase III development. If successful, the partners plan to move the candidate into phase III in the second quarter.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.